Cargando…

Regression of metastatic melanoma by targeting cancer stem cells

Current therapeutic regimens attempt to eliminate all malignant cells of a melanoma lesion. Pre-clinical data, however, indicate that melanoma is maintained by a minor subset of cancer cells, which are characterized by CD20 expression. We attempted to eliminate those cells in a progressing, chemothe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schlaak, Max, Schmidt, Patrick, Bangard, Christopher, Kurschat, Peter, Mauch, Cornelia, Abken, Hinrich
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2012
Materias:	Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3292889/ https://www.ncbi.nlm.nih.gov/pubmed/22289880

Ejemplares similares

The use of circulating cell-free tumor DNA in routine diagnostics of metastatic melanoma patients
por: Knuever, Jana, et al.
Publicado: (2020)

The beating heart of melanomas: a minor subset of cancer cells sustains tumor growth
por: Schmidt, Patrick, et al.
Publicado: (2011)

Successful Treatment of a Panniculitis-Like Primary Cutaneous T-Cell Lymphoma of the α/β Type with Bexarotene
por: Zhang, X., et al.
Publicado: (2012)

Successful Treatment of Myasthenia Gravis Following PD-1/CTLA-4 Combination Checkpoint Blockade in a Patient With Metastatic Melanoma
por: Werner, Jan-Michael, et al.
Publicado: (2019)

Oligometastatic disease and visceral resections in advanced malignant melanoma: a propensity-matched analysis
por: Urbanski, Alexander, et al.
Publicado: (2023)

Cancer therapy – molecular targets in tumour–host interactions
por: Kurschat, P, et al.
Publicado: (2006)

Spontaneous regression of pulmonary metastatic melanoma
por: Ong, Sook Fen, et al.
Publicado: (2015)

The epidermal polarity protein Par3 is a non–cell autonomous suppressor of malignant melanoma
por: Mescher, Melina, et al.
Publicado: (2017)

Targeting two co-operating cytokines efficiently shapes immune responses
por: Hombach, Andreas A., et al.
Publicado: (2013)

Bilateral neuroretinitis and anterior uveitis following ipilimumab treatment for metastatic melanoma
por: Hahn, Laura, et al.
Publicado: (2016)

Immune checkpoint inhibitor‐related gastritis in a patient with metastatic melanoma
por: Sugiyama, Yuya, et al.
Publicado: (2021)

Metastatic melanoma with spontaneous complete regression of a thick primary lesion
por: Khosravi, Hasan, et al.
Publicado: (2016)

Metastatic Malignant Melanoma of Parotid Gland with a Regressed Primary Tumor
por: Kılıçkaya, M. Mustafa, et al.
Publicado: (2016)

Regression of pigmented lesions in a patient with metastatic melanoma treated with immunotherapy
por: Schwager, Zachary, et al.
Publicado: (2018)

Building on Synthetic Immunology and T Cell Engineering: A Brief Journey Through the History of Chimeric Antigen Receptors
por: Abken, Hinrich
Publicado: (2021)

Primary and Metastatic Cutaneous Melanomas Discriminately Enrich Several Ligand-Receptor Interactions
por: Diaz, Michael J., et al.
Publicado: (2023)

Durable tumor regression in highly refractory metastatic KIT/PDGFRA wild-type GIST following treatment with nivolumab
por: Schroeder, Brett A., et al.
Publicado: (2020)

Improved Activation toward Primary Colorectal Cancer Cells by Antigen-Specific Targeting Autologous Cytokine-Induced Killer Cells
por: Schlimper, Claudia, et al.
Publicado: (2012)

OTHR-14. TREATMENT MONITORING OF IMMUNOTHERAPY AND TARGETED THERAPY USING FET PET IN PATIENTS WITH MELANOMA AND LUNG CANCER BRAIN METASTASES: INITIAL EXPERIENCES
por: Galldiks, Norbert, et al.
Publicado: (2019)

Engineered T Cells for the Adoptive Therapy of B-Cell Chronic Lymphocytic Leukaemia
por: Koehler, Philipp, et al.
Publicado: (2012)

Incidental regression of an advanced basal cell carcinoma after ipilimumab exposure for metastatic melanoma
por: Mohan, Shalini V., et al.
Publicado: (2016)

Nivolumab plus ipilimumab in metastatic uveal melanoma: a real-life, retrospective cohort of 47 patients
por: Salaün, Hélène, et al.
Publicado: (2022)

Proximity of immune and tumor cells underlies response to BRAF/MEK-targeted therapies in metastatic melanoma patients
por: Yan, Chi, et al.
Publicado: (2022)

Chimeric antigen receptors designed to overcome transforming growth factor‐β‐mediated repression in the adoptive T‐cell therapy of solid tumors
por: Hartley, Jordan, et al.
Publicado: (2019)

CAR T Cells: A Snapshot on the Growing Options to Design a CAR
por: Holzinger, Astrid, et al.
Publicado: (2019)

Do Treg Speed Up with CARs? Chimeric Antigen Receptor Treg Engineered to Induce Transplant Tolerance
por: Kaljanac, Marcell, et al.
Publicado: (2022)

CAR T cell therapy becomes CHIC: “cytokine help intensified CAR” T cells
por: Thomas, Simone, et al.
Publicado: (2023)

Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2
por: Clark, Joseph I, et al.
Publicado: (2021)

Hemorrhagic choroidal melanoma
por: Oellers, Patrick, et al.
Publicado: (2018)

Development of Lymphopenia during Therapy with Immune Checkpoint Inhibitors Is Associated with Poor Outcome in Metastatic Cutaneous Melanoma
por: Tomsitz, Dirk, et al.
Publicado: (2022)

Use Patterns and Costs of Isolated Limb Perfusion and Infusion in the Treatment of Regional Metastatic Melanoma: A Retrospective Database Analysis
por: Ma, Qiufei, et al.
Publicado: (2016)

Spontaneous Regression of Primary Melanoma and Multiple Melanocytic Nevi in a Patient With Metastatic Melanoma
por: Paolino, Giovanni, et al.
Publicado: (2020)

International Regensburg Center for Interventional Immunology (RCI) symposium on “Synthetic immunology and environment-adapted redirection of T cells”, 17–18 July, 2019, Regensburg, Germany
por: Beckhove, Philipp, et al.
Publicado: (2020)

TIGIT(+) NK cells in combination with specific gut microbiota features predict response to checkpoint inhibitor therapy in melanoma patients
por: Tsakmaklis, Anastasia, et al.
Publicado: (2023)

Clinical determinants of long-term survival in metastatic uveal melanoma
por: Koch, Elias A. T., et al.
Publicado: (2021)

Young T Cells Age During a Redirected Anti-Tumor Attack: Chimeric Antigen Receptor-Provided Dual Costimulation is Half the Battle
por: Hombach, Andreas A., et al.
Publicado: (2013)

Most Do, but Some Do Not: CD4(+)CD25(−) T Cells, but Not CD4(+)CD25(+) Treg Cells, Are Cytolytic When Redirected by a Chimeric Antigen Receptor (CAR)
por: Hombach, Andreas A., et al.
Publicado: (2017)

Endosialin Expression in Metastatic Melanoma Tumor Microenvironment Vasculature: Potential Therapeutic Implications
por: Kiyohara, Eiji, et al.
Publicado: (2015)

Anaplastic pleomorphic xanthoastrocytoma with epithelioid morphology misdiagnosed and treated as melanoma
por: Dorostkar, Mario M, et al.
Publicado: (2022)

Spontaneous regression of a metastatic melanoma pulmonary deposit following biopsy
por: Behnia, Fatemeh, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_3qptgct9r0gi0rb2cpi5281dcn